Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GeoVax Labs, Inc. - Common Stock (NQ:GOVX)

0.8295 -0.0729 (-8.08%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GeoVax Labs, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
GeoVax Labs Retains CATO SMS To Manage Its Mid-Stage COVID-19 Vaccine Trials
GeoVax Labs Inc (NASDAQ: GOVX) has engaged CATO SMS to manage its two ongoing Phase 2 trials of its COVID-19 vaccine candidate, GEO-CM04S1. One is testing the... 
Via Benzinga
GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
Data Published in a Lancet Journal on COH04S1, a City of Hope-Developed COVID-19 Vaccine, Shows it Produced Robust Antibodies and T cells Against SARS-CoV-2
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
Geovax Labs: Q4 Earnings Insights
Geovax Labs (NASDAQ:GOVX) reported its Q4 earnings results on Wednesday, March 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Geovax... 
Via Benzinga
GeoVax Reports 2021 Year-End Financial Results and Provides Corporate Update
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
Earnings Scheduled For March 9, 2022
Companies Reporting Before The Bell • REV Group (NYSE:REVG) is expected to report quarterly earnings at $0.11 per share on revenue of $529.44 million. • Express (... 
Via Benzinga
Earnings Preview For Geovax Labs
Geovax Labs (NASDAQ:GOVX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-09. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
GeoVax Announces Key Staff Appointments
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax to Report 2021 Financial Results on Wednesday, March 9, 2022 and Provide Corporate Update
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax CEO Selected as a Recipient of the 2022 Georgia Titan 100
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Present at the 2022 BIO CEO & Investor Digital Conference
Atlanta, GA - (NewMediaWire) - February 08, 2022 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that... 
Via NewMediaWire
Exposures COVID-19
GeoVax Announces Closing of $10 Million Private Placement
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers ATI Physical Therapy (NYSE:ATIP) stock increased by 22.7% to $3.73 during Friday's regular session. Trading volume for ATI Physical Therapy's stock is 14.3... 
Via Benzinga
GeoVax Announces $10 Million Private Placement
Atlanta, GA - (NewMediaWire) - January 14, 2022 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it... 
Via NewMediaWire
GeoVax Retains CATO SMS To Manage Gedeptin Phase 1/2 Clinical Trial
GeoVax Labs, Inc. (NASDAQ: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the engagement of CATO SMS to... 
Via Benzinga
GeoVax Retains CATO SMS to Manage Gedeptin Phase 1/2 Clinical Trial
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax Appoints Dr. Kelly McKee as Chief Medical Officer
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
GeoVax to Participate in Upcoming Life Sciences Investor Conferences
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax Issues Shareholder Update Letter
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
23 Stocks Moving in Tuesday's Pre-Market Session
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 62.1% to $1.05 in pre-market trading as the company issued a clinical and corporate update. NeuroBo Pharmaceuticals, Inc... 
Via Benzinga
GeoVax Initiates Phase 2 Trial For COVID-19 Vaccine Booster
GeoVax Labs Inc (NASDAQ: GOVX) initiated vaccine dosing in the Phase 2 portion of its Phase 1/2 trial of COH04S1 COVID-19 vaccine to target both the spike (S) and... 
Via Benzinga
GeoVax Announces Initiation of Phase 2 Clinical Trial for COVID-19 Vaccine Booster
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
GeoVax Receives Notice of Allowance for Malaria Vaccine Patent
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
GeoVax Presents Hemorrhagic Fever Vaccine Data at the World Vaccine & Immunotherapy Congress
Nonhuman Primate Testing of Sudan and Marburg Vaccine Candidates Demonstrates Efficacious Immune Response 
Via NewMediaWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
GeoVax Presents COVID-19 Vaccine Data at the World Vaccine & Immunotherapy Congress
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, traders! We're starting off the day right with a look at the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
23 Stocks Moving in Wednesday's Pre-Market Session
Gainers Skylight Health Group Inc. (NASDAQ: SLHG) rose 55.3% to $2.05 in pre-market trading after dipping around 10% on Tuesday. Skylight Health Group, last month, posted a... 
Via Benzinga
33 Stocks Moving In Monday's Mid-Day Session
Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares jumped 116.4% to $86.13 after the company announced positive topline results from the GEM-3 Phase 3 trial of investigational... 
Via Benzinga
50 Biggest Movers From Yesterday
Gainers Krystal Biotech, Inc. (NASDAQ: KRYS) shares surged 121.7% to close at $88.24 on Monday after the company announced positive topline results from the GEM-3 Phase 3 trial... 
Via Benzinga
56 Biggest Movers From Friday
Gainers iSpecimen Inc. (NASDAQ: ISPC) climbed 71.7% to settle at $17.51 on Friday. The company recently announced it has been contracted to support new advanced research on... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.